Multiple Sclerosis (MS) Drug Market

RECENT NEWS  Sep 16  Comment 
BERLIN (dpa-AFX) - Merck KGaA (MKGAY.PK) announced that it presented new efficacy data for investigational Cladribine Tablets in two oral presentations at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis...  Sep 14  Comment 
WESTON (dpa-AFX) - Biogen Inc. (BIIB) Wednesday said new real-world and clinical evidence demonstrates Tecfidera consistently delivered strong, sustained efficacy in newly-diagnosed and previously treated patients with relapsing-remitting multiple...
MarketWatch  Sep 14  Comment 
Biogen Inc. on Wednesday reported positive new data for its multiple sclerosis treatment Tecfidera in clinical and real-world settings. The biotech said the drug significantly reduced the time to a first relapse versus other treatments and...  Sep 14  Comment 
SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a member of the Roche group (RHHBY), announced new analyses from the three OCREVUS or ocrelizumab Phase III studies in relapsing multiple sclerosis or RMS and primary progressive multiple sclerosis or...  Sep 1  Comment 
NOVARTIS FINANCE S.A. / Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for...
Forbes  Aug 29  Comment 
How does the immune system work? How does it distinguish between friend and foe—the foreign structures worthy of attack, and the healthy tissues to leave alone? What makes the immune system go haywire and start attacking healthy nerve tissue,...
FierceBiotech  Aug 25  Comment 
Novartis touts positive data from PhIII multiple sclerosis trial slawrence Thu, 08/25/2016 - 11:13  Aug 25  Comment 
NOVARTIS FINANCE S.A. / Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the...


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki